Edwards Lifesciences Files 8-K on Financials
Ticker: EW · Form: 8-K · Filed: Apr 25, 2024 · CIK: 1099800
| Field | Detail |
|---|---|
| Company | Edwards Lifesciences Corp (EW) |
| Form Type | 8-K |
| Filed Date | Apr 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: EW
TL;DR
Edwards Lifesciences dropped an 8-K on April 25th detailing their financial results.
AI Summary
Edwards Lifesciences Corporation filed an 8-K on April 25, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the period ending April 25, 2024.
Why It Matters
This 8-K filing provides crucial updates on Edwards Lifesciences' financial performance and condition, which can impact investor decisions and stock valuation.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Edwards Lifesciences Corporation (company) — Registrant
- April 25, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Irvine, California (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Edwards Lifesciences Corporation.
When was this 8-K report filed?
This 8-K report was filed on April 25, 2024.
What is the state of incorporation for Edwards Lifesciences Corporation?
Edwards Lifesciences Corporation is incorporated in Delaware.
Where are the principal executive offices of Edwards Lifesciences Corporation located?
The principal executive offices of Edwards Lifesciences Corporation are located in Irvine, California.
What SEC Act is this filing made pursuant to?
This filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 479 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-04-25 16:23:35
Key Financial Figures
- $1.00 — ich registered Common Stock, par value $1.00 per share EW New York Stock Exchange
Filing Documents
- ew-20240425.htm (8-K) — 34KB
- ex-991q12024.htm (EX-99.1) — 357KB
- ew45percentblacklrga21a.jpg (GRAPHIC) — 625KB
- 0001099800-24-000037.txt ( ) — 1394KB
- ew-20240425.xsd (EX-101.SCH) — 2KB
- ew-20240425_lab.xml (EX-101.LAB) — 21KB
- ew-20240425_pre.xml (EX-101.PRE) — 12KB
- ew-20240425_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On April 25, 2024, Edwards Lifesciences Corporation, a Delaware corporation ("Edwards"), issued a press release setting forth Edwards' financial results for the first quarter of 2024. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated April 25, 2024, reporting Edwards' financial results for the first quarter of 2024. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 25, 2024 EDWARDS LIFESCIENCES CORPORATION By: /s/ Scott B. Ullem Scott B. Ullem Chief Financial Officer 3 Exhibit Index Exhibit Number Description 99.1 Press release, dated April 25 , 2024, reporting Edwards' financial results for the first quarter of 202 4 . 4